Lupin, Fuji Agree For Commercialisation Of Nextstellis In Vietnam & Philippines

Global pharma major Lupin has signed a licence and supply agreement with OLIC (Thailand), a subsidiary of Japanese pharmaceutical company Fuji Pharma, for marketing Nextstellis (drospirenone and estetrol tablets) in Vietnam and Philippines.

Nextstellis is a novel combination medication consisting of drospirenone (DRSP) and estetrol (E4), indicated for use by women of reproductive age to prevent pregnancy.

“We are delighted to collaborate with Fuji and OLIC to offer NextstellisTM to our patients in Vietnam and the Philippines. This new addition to our Women’s Health portfolio will strengthen our commitment to expand healthcare options worldwide,” said Fabrice Egros, President – Corporate Development and Growth Markets, Lupin.

Fuji is a Tokyo Stock Exchange (TSE) listed, Japan‐based pharmaceutical company mainly engaged in the manufacture and sale of prescription based pharmaceutical products. According to the company, Fuji focuses on the field of women's health care with a wide variety of new and generic drugs for women's specific diseases such as infertility, dysmenorrhea, endometriosis, contraception and menopausal disorders. Fuji aims to be a leading company in women's healthcare and support the health of women of all ages.

Whereas, Lupin is a pharmaceutical company headquartered in Mumbai, India. The Company develops and commercialises a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle East regions, as per the media release.

The Company says that it has a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas.

Lupin is the third-largest pharmaceutical company in the US by prescriptions. The company invested 7.8 per cent of its revenue in research and development in FY24.